Summary
The pharmacokinetics of oral nicorandil 20 mg 12 hourly for 9 doses was evaluated in 21 hospitalized patients with angina pectoris due to coronary heart disease and with normal and impaired renal function. Patients were divided into 3 groups based on creatinine clearance (CLCr): GROUP I (n=6) > 80 ml/min, GROUP II (n=8) 20–80 ml/min, and GROUP III (n=7) < 20 ml/min.
After the first dose, the total clearance of nicorandil (CL) value did not change with increasing renal failure and so was not dependent on creatinine clearance. After the last dose CL was 51 l·h−1 in Group I, 44 l·h−1 in Group II and 56 l·h−1 in Group III, and it was not related to creatinine clearance. The percentage of the dose excreted in the urine was 0.4%. No significant difference was noted in any of the other pharmacokinetic parameters examined in the three groups, not even on comparing values obtained on the first and last days of treatment.
The findings suggest that there is no need to change the dose of nicorandil in subjects with different degrees of renal failure.
Similar content being viewed by others
References
Uchida Y, Yoshimoto N, Murao S (1977) Effect of 2-nicotinamidoethyl nitrate (SG 75) on coronary circulation. Jpn Heart J 19: 112–124
Sakai K (1989) Nicorandil: animal pharmacology. Am J Cardiol 63: 2J-3J
Leonetti G, Fruscio M, Gradnik R, Chianca R, Bolla GB, Prandi P, Zanchetti A (1989) Nicorandil, a new vasodilator drug, in patients with essential hypertension. J Hypertens Bull 7: S292–293
Gali N, Varani E, Maiello L, Boriani G, Boschi S, Binetti G, Magnani B (1990) Usefulness of nicorandil in congestive heart failure. Am J Cardiol 65: 343–348
Katagiri T, Mochizuki M, Umetsu K, Hiroshige J, Geshi E, Konno N (1989) Protection of acute ischemic myocardial injury by pharmacological intervention. Jpn Circ J 53: 1108–1114
Inoue I, Nakaya Y, Nakaya S, Mori H (1989) Extracellular Ca2+-activated in coronary artery smooth muscle cells and its role in vasodilation. FEBS Lett 255: 281–284
Sakai K, Shiraki Y, Nabata H (1981) Cardiovascular effects of a new coronary vasodilator SG 75: comparison with nitroglycerine and diltiazem. J Cardiovasc Pharmacol 3: 139–150
Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M (1983) Effectiveness of Nicorandil (SG 75), a new long-acting drug with nitroglycerin effect, in patients with coronary artery disease: improved left ventricular function and regional wall motion and abolition of pacing-induced angina. J Cardiovasc Pharmacol 5: 371–377
Taira N, Satho K, Yanagisawa T, Imai Y, Hiwatari M (1979) Pharmacological profile of a new coronary vasodilator drug: 2-nicotinamidoethyl nitrate (SG 75). Clin Exp Pharmacol Physiol 6: 301–316
Mizukami M, Tamoike H, Inou T, Watanabe K, Kikuchi Y, Nakamura M (1981) Effect of 2-nicotinamidoethyl nitrate (SG 75) and/or nitroglycerin on systemic hemodynamics and coronary blood flow in conscious dogs. Drug Res 31: 1244–1247
Preuss KC, Gross GJ, Brooks HL, Waltier DC (1985) Hemodynamic action of nicorandil, a new antianginal agent with conscious dog. J Cardiovasc Pharmacol 7: 709–714
Suryapranata H, Serruys PW, De Feyter PJ, Werdouw PD, Hugenholts PG (1988) Coronary vasodilatory actions after a single dose of nicorandil. Am J Cardiol 61: 292–297
Hisa Y, Hamai K, Wada T, Aihara T, Bando M, Nakai Y, Kataoka Y (1989) Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris. Tokushima J Exp Med 36: 65–70
Tice FD, Binkley PF, Cody RJ, Moeschberger ML, Mohrland JS, Wolf DL, Leier CV (1990) Hemodynamic effects of oral nicorandil in congestive heart failure. Am J Cardiol 65: 1361–1367
Henry PJ, Horowitz JD, Louis WJ (1990) Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol 15: 365–370
Kambara H, Nakamura Y, Tamaki S, Kawai C (1987) Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function. J Cardiovasc Pharmacol 10 [Suppl 8]: S104-S108
Sakai K, Ohba Y, Akima M, Kamiyama H, Hinohara Y, Nakano H (1980) Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG 75). Jpn J Pharmacol 30: 881–890
Belz GG, Matthews J, Heinrich J, Wagner G (1984) Controlled comparison of the pharmacodynamic effects of nicorandil (SG 75) and isosorbide dinitrate in man. Eur J Clin Pharmacol 26: 681–685
Nabata H, Shiraki Y, Sakai K (1981) Development of tolerance and a new coronary vasodilator, N(2-hydroxyethyl)nicotinamide nitrate (SG 75): a comparsion with nitroglycerin. Jpn J Pharmacol 31: 511–519
Kuronaru O, Sakai K (1986) Comparison of development of tolerance between nicorandil and nitroglycerine in anaesthetized open-chest dogs. Jpn J Pharmacol 42: 199–208
Sakai K, Kuronaro O (1987) Nitrate tolerance: comparison of nicorandil isosorbide dinitrate and nitroglycerine in anaesthetized dogs. J Cardiovasc Pharmacol 10 [Suppl 8]: S517-S524
Tadeka K, Nakagawa Y, Katano Y, Imai S (1977) Effects of coronary vasodilators on large and small coronary arteries of dogs. Jpn Heart J 18: 92–101
Silke B, Verma SP, Ali MS, Goldhammer E, Taylor SH (1989) Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induce angina pectoris. Am J Cardiol 63: 49J-55J
Kobayashi K, Hakuta T (1987) Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine and propanolol. J Cardiovasc Pharmacol 10 [Suppl 8]: S109-S115
Coltart DJ, Signy M (1989) Acute hemodynamic effects of single dose nicorandil in coronary artery disease. Am J Cardiol 63 (21): 34J-39J
Camm AJ, Maltz MB (1989) A controlled single dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 63: 61J-65J
Meany TB, Richardson P, Camm AJ, Coltar J, Griffith M, Maltz MB, Signy M (1989) Exercise capacity after single and twice daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 63: J66-J70
Frydman AM, Chappele P, Diekmann H, Bruno R, Thebauld JJ, Bouthier J, Caplain H, Ungethuem W, Gaillard C, Le Liboux J, Renard A, Gaillot J (1989) Pharmacokinetics of nicorandil. Am J Cardiol 63: 25J-33J
Solal AC, Jaeger P, Bouthier J, Juliard JM, Dahan M, Gourgon R (1989) Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 63: 44J-48J
Ishisaki T, Chiba K, Sakanuma T, Sasaki T, Kamiyama H, Nakano H (1984) Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. J Pharm Sci 73: 494–498
Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M (1979) Pharmacological profile of a new coronary vasodilator drug 2-nicotinamidoethyl nitrate (SG 75). Clin Exp Pharmacol Physiol 6: 301–316
Horii D, Ishibashi A, Iwamoto A, Yakuri R (1984) Study of the bioavailability of nicorandil before and after meals. Clin Pharmacol 15 (4): 489–495
Sakai K, Nakano H, Nagano H, Uchida Y (1983) Nicorandil. In: Scriabine A (ed) New drug annual: cardiovascular drug. Raven Press, New York
Benet LZ, Galeazzi RL (1979) Non-compartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Molinaro, M., Villa, G., Regazzi, M.B. et al. Pharmacokinetics of nicorandil in patients with normal and impaired renal function. Eur J Clin Pharmacol 42, 203–207 (1992). https://doi.org/10.1007/BF00278485
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278485